Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient

Chimaobi Anugwom; Thomas Leventhal

doi:10.14309/crj.0000000000000416

Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient

Chimaobi Anugwom, Thomas Leventhal

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer treatment has taken giant strides in recent years with the advent of immunotherapy, including checkpoint inhibitors. The use of these medications in liver transplant recipients has been debated, and the added effect of previous hepatitis C infection on the immune system in this setting, is poorly understood. We present a case of cholestatic hepatitis after the treatment of recurrent hepatocellular carcinoma with nivolumab in the post-transplant period. Understanding the pathophysiology is relevant to improving the management of this type of liver injury and expanding our knowledge of programmed death-1 inhibitors in liver transplant recipients.

Original language	English (US)
Pages (from-to)	e00416
Journal	ACG Case Reports Journal
Volume	7
Issue number	7
DOIs	https://doi.org/10.14309/crj.0000000000000416
State	Published - Jul 2020

Bibliographical note

PubMed: MeSH publication types

Case Reports

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.14309/crj.0000000000000416

Find It

Find It at U of M Libraries

Cite this

@article{ab8898d4a5b148bda97f2fc9260e924d,

title = "Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient",

abstract = "Cancer treatment has taken giant strides in recent years with the advent of immunotherapy, including checkpoint inhibitors. The use of these medications in liver transplant recipients has been debated, and the added effect of previous hepatitis C infection on the immune system in this setting, is poorly understood. We present a case of cholestatic hepatitis after the treatment of recurrent hepatocellular carcinoma with nivolumab in the post-transplant period. Understanding the pathophysiology is relevant to improving the management of this type of liver injury and expanding our knowledge of programmed death-1 inhibitors in liver transplant recipients.",

author = "Chimaobi Anugwom and Thomas Leventhal",

note = "{\textcopyright} 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.",

year = "2020",

month = jul,

doi = "10.14309/crj.0000000000000416",

language = "English (US)",

volume = "7",

pages = "e00416",

journal = "ACG Case Reports Journal",

issn = "2326-3253",

publisher = "American College of Gastroenterology",

number = "7",

}

TY - JOUR

T1 - Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient

AU - Anugwom, Chimaobi

AU - Leventhal, Thomas

PY - 2020/7

Y1 - 2020/7

N2 - Cancer treatment has taken giant strides in recent years with the advent of immunotherapy, including checkpoint inhibitors. The use of these medications in liver transplant recipients has been debated, and the added effect of previous hepatitis C infection on the immune system in this setting, is poorly understood. We present a case of cholestatic hepatitis after the treatment of recurrent hepatocellular carcinoma with nivolumab in the post-transplant period. Understanding the pathophysiology is relevant to improving the management of this type of liver injury and expanding our knowledge of programmed death-1 inhibitors in liver transplant recipients.

AB - Cancer treatment has taken giant strides in recent years with the advent of immunotherapy, including checkpoint inhibitors. The use of these medications in liver transplant recipients has been debated, and the added effect of previous hepatitis C infection on the immune system in this setting, is poorly understood. We present a case of cholestatic hepatitis after the treatment of recurrent hepatocellular carcinoma with nivolumab in the post-transplant period. Understanding the pathophysiology is relevant to improving the management of this type of liver injury and expanding our knowledge of programmed death-1 inhibitors in liver transplant recipients.

U2 - 10.14309/crj.0000000000000416

DO - 10.14309/crj.0000000000000416

M3 - Article

C2 - 32766358

SN - 2326-3253

VL - 7

SP - e00416

JO - ACG Case Reports Journal

JF - ACG Case Reports Journal

IS - 7

ER -

Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Fingerprint

Cite this